A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate

J Med Chem. 1984 Dec;27(12):1602-7. doi: 10.1021/jm00378a013.

Abstract

In studies on antitumor antibody-cytotoxic drug conjugates as potential antitumor agents with improved tumor specificity, daunomycin (DM) was first linked to a poly-L-glutamic acid (PLGA) derivative having a single masked thiol group. At the thiol group, DM-linked PLGA was bound to horse anti-rat alpha-fetoprotein (AFP) antibody. The anti-AFP antibody-PLGA-DM conjugate (anti-AFP conjugate, DM/PLGA/Ig molar binding ratio, 7.5/1.2/1.0) retained most of the antigen-binding activity of the parent antibody and was more potent than either unconjugated DM, a conjugate similarity prepared with normal horse immunoglobulin (normal conjugate), or an unconjugated mixture of anti-AFP antibody and DM in an in vitro cytotoxicity assay against the AFP-producing rat ascites hepatoma cell line AH66. Anti-AFP conjugate tended to be less cytotoxic than DM against the AFP-nonproducing rat ascites hepatoma AH272 cells, and in this case there was no difference between the cytotoxicities of anti-AFP conjugate and of normal conjugate.

MeSH terms

  • Animals
  • Antibodies / chemical synthesis*
  • Antibodies / toxicity
  • Cell Line
  • Cell Survival / drug effects
  • Daunorubicin / chemical synthesis*
  • Daunorubicin / toxicity*
  • Drug Evaluation, Preclinical
  • Immune Sera
  • Indicators and Reagents
  • Liver Neoplasms, Experimental / pathology
  • Rats
  • Spectrophotometry, Ultraviolet
  • alpha-Fetoproteins*

Substances

  • Antibodies
  • Immune Sera
  • Indicators and Reagents
  • alpha-Fetoproteins
  • anti-alpha-fetoprotein antibody-daunomycin conjugate
  • Daunorubicin